Monday, February 20, 2006

Tesmilifene for advanced breast cancer wins fast review by US Regulators

Reuter's, February 13, 2006
YM BioSciences Inc., a Canadian biopharmaceutical company, said U.S. regulators agreed to a "fast track" review of its lead drug, tesmilifene, for the treatment of breast cancer. The drug is used in combination with an anthracycline chemotherapeutic for the treatment of women with advanced breast cancer. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */